Introduction {#s1}
============

Esophageal cancer was the fourth leading cause of cancer death and the fifth most commonly diagnosed cancer in China in 2009 [@pone.0087783-Chen1]. Genetic factors, such as single nucleotide polymorphisms (SNPs), might play an important role in the carcinogenesis of esophageal squamous cell carcinoma (ESCC) [@pone.0087783-Gu1].

N-acetyltransferase 2 (NAT2) is an enzyme that plays an essential role in the metabolism of various potential carcinogens. NAT2 is mainly expressed in the human liver and gastrointestinal tract. The *NAT2* gene is located on 8p21.3-23.1 and encodes a 290-amino acid protein, NAT2 [@pone.0087783-Blum1]. *NAT2* is polymorphic, and it was thought that NAT2 acetylation status alteration caused by *NAT* polymorphisms decreased enzymatic activity and result in absence of detoxification efficiency, which could lead to an increase in cancer susceptibility [@pone.0087783-GarciaMartin1]. It has been reported that *NAT2* polymorphisms and/or their interaction with smoking is associated with various types of malignancies.

Genetic variation of *NAT2* may lead to differences in the rate of arylamine metabolism and consequently increase cancer risk [@pone.0087783-Walker1]. The substrates for NAT2 that are involved in carcinogenesis, are represented mainly by heterocyclic amines and polycyclic aromatic hydrocarbon rings found in cooked or smoked meat [@pone.0087783-Layton1] and cigarette smoke [@pone.0087783-Manabe1].

*NAT2* genetic variations may contribute to the development of ESCC. In a hospital-based case-control study, we performed genotyping analyses of ten *NAT2* tagging SNPs in 629 ESCC cases and 686 controls in a Chinese population.

Materials and Methods {#s2}
=====================

Ethical approval of the study protocol {#s2a}
--------------------------------------

The Review Board of Jiangsu University (Zhenjiang, China) approved this hospital-based case-control study. We have complied with the World Medical Association Declaration of Helsinki regarding ethical conduct of research involving human subjects and/or animals. All subjects provided written, informed consent to be included in the study.

Patients and Controls {#s2b}
---------------------

Six hundred and twenty-nine subjects with esophageal cancer were consecutively recruited from the Affiliated People\'s Hospital of Jiangsu University and Affiliated Hospital of Jiangsu University (Zhenjiang, China) between October 2008 and December 2010. All cases of esophageal cancer were diagnosed as ESCC pathologically. The exclusion criteria were patients who had previously had: cancer; any metastasized cancer; radiotherapy or chemotherapy. The 686 controls were patients without cancer and were matched to the cases with regard to age (±5 years) and sex. They were recruited from the two hospitals mentioned above during the same time period. Most of the controls were admitted to the hospitals for the treatment of trauma.

Trained interviewers, using a pre-tested questionnaire, questioned each subject personally to obtain information on demographic data (e.g., age, sex) and related risk factors (including tobacco smoking and alcohol consumption). After the interview, 2-mL samples of venous blood were collected from each subject. Individuals who smoked one cigarette per day for \>1 year were defined as "smokers". Subjects who consumed more than three alcoholic drinks a week for \>6 months were considered to be "alcohol drinkers".

Isolation of DNA, SNPs selection and genotyping by ligation detection reaction {#s2c}
------------------------------------------------------------------------------

Blood samples were collected from patients using Vacutainers and transferred to tubes lined with ethylenediamine tetra-acetic acid (EDTA). Genomic DNA was isolated from whole blood with the QIAamp DNA Blood Mini Kit (Qiagen, Berlin, Germany) [@pone.0087783-Wei1]. We used a block-based tagging strategy to find tagging SNPs using Haploview 4.2 software, according to the HapMap database (<http://www.hapmap.org/>, phase II Nov08, on NCBI B36 assembly, dbSNP b126; population: Chinese Han population); minor allele frequency (MAF)≥0.05, Hardy-Weinberg equilibrium (HWE) *p*≥0.05 and call rate ≥95%) on the basis of pairwise linkage disequilibrium r^2^ threshold of 0.8. Ten *NAT2* tagging SNPs were thus selected. The samples were genotyped using the ligation detection reaction (LDR) method, with technical support from the Shanghai Biowing Applied Biotechnology Company [@pone.0087783-Chen2], [@pone.0087783-Yin1]. For quality control, repeated analyses were done for 160 (12.17%) randomly selected samples with high DNA quality.

Statistical Analyses {#s2d}
--------------------

Differences in the distributions of demographic characteristics, selected variables, and genotypes of the *NAT2* variants between the cases and controls were evaluated using the *χ* ^2^ test. The associations between the ten SNPs and risk of ESCC were estimated by computing the odds ratios (ORs) and their 95% confidence intervals (CIs) using logistic regression analyses for crude ORs and adjusted ORs when adjusting for age, sex, smoking and drinking status. The Bonferroni correction procedure was applied because of the number of comparisons. The HWE was tested by a goodness-of-fit *χ* ^2^ test to compare the observed genotype frequencies to the expected frequencies among the control subjects. All statistical analyses were performed with SAS 9.1.3 (SAS Institute, Cary, NC, USA).

Results {#s3}
=======

Characteristics of the study population {#s3a}
---------------------------------------

Characteristics of cases and controls included in the study are summarized in [Table 1](#pone-0087783-t001){ref-type="table"}. The cases and controls appeared to be adequately matched on age and sex as suggested by the *χ* ^2^ tests. As shown in [Table 1](#pone-0087783-t001){ref-type="table"}, significant difference was detected on smoking status between the cases and the controls, and drinking rate was higher in ESCC patients than in control subjects. The primary information for eight genotyped SNPs was in [Table 2](#pone-0087783-t002){ref-type="table"}. The concordance rates of repeated analyses were 100% except *NAT2* rs11996129 T\>C (157/160, 98.13%), rs1565684 T\>C (159/160, 99.38%) and rs1799930 G\>A (159/160, 99.38%). MAF in our controls was similar to MAF for Chinese in database for all SNPs. The observed genotype frequencies for these ten polymorphisms in the controls were all in HWE except *NAT2* rs4540438 A\>C (*p* = 0.015) ([Table 2](#pone-0087783-t002){ref-type="table"}).

10.1371/journal.pone.0087783.t001

###### Distribution of selected demographic variables and risk factors in ESCC cases and controls.

![](pone.0087783.t001){#pone-0087783-t001-1}

  Variable                     Cases (n = 629)   Controls (n = 686)   *p* [a](#nt101){ref-type="table-fn"}          
  --------------------------- ----------------- -------------------- -------------------------------------- ------- -------------
  **Age (years)** mean ± SD     62.85 (±8.13)      62.58 (±7.89)                     0.541                          
  **Age (years)**                                                                                                       0.155
  \<63                               310               49.28                          365                    53.21  
  ≥63                                319               50.72                          321                    46.79  
  **Sex**                                                                                                               0.185
  Male                               444               70.59                          461                    67.20  
  Female                             185               29.41                          225                    32.80  
  **Tobacco use**                                                                                                    **\<0.001**
  Never                              355               56.44                          499                    72.74  
  Ever                               274               43.56                          187                    27.26  
  **Alcohol use**                                                                                                    **\<0.001**
  Never                              428               68.04                          526                    76.68  
  Ever                               201               31.96                          160                    23.32  

Two-sided *χ* ^2^ test and student t test; Bold values are statistically significant (*p*\<0.05).

10.1371/journal.pone.0087783.t002

###### Primary information for *NAT2* rs1041983 C\>T, rs11780884 A\>G, rs11996129 T\>C, rs12674710 C\>A, rs1390359 C\>A, rs1390360 G\>A, rs1565684 T\>C, rs1799930 G\>A, rs1799931 G\>A and rs4540438 A\>C polymorphisms.
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  Genotyped SNPs                                                            *NAT2* rs1041983 C\>T   *NAT2* rs11780884 A\>G   *NAT2* rs11996129 T\>C   *NAT2* rs12674710 C\>A   *NAT2* rs1390359 C\>A   *NAT2* rs1390360 G\>A   *NAT2* rs1565684T\>C   *NAT2* rs1799930 G\>A   *NAT2* rs1799931 G\>A   *NAT2* rs4540438 A\>C
  ------------------------------------------------------------------------ ----------------------- ------------------------ ------------------------ ------------------------ ----------------------- ----------------------- ---------------------- ----------------------- ----------------------- -----------------------
  Chromosome                                                                          8                       8                        8                        8                        8                       8                      8                       8                       8                       8
  Gene Official Symbol                                                              NAT2                     NAT2                     NAT2                     NAT2                    NAT2                    NAT2                    NAT2                   NAT2                    NAT2                    NAT2
  Function                                                                        cds-synon                No Data               intron region               No Data                  No Data                 No Data                No Data                missense                missense                 No Data
  Chr Pos (Genome Build 36.3)                                                     18302075                 18290333                 18298855                 18307943                18305609                18305773                18290944               18302383                18302650                18307883
  Regulome DB Score[a](#nt102){ref-type="table-fn"}                                   5                    No Data                  No Data                  No Data                  No Data                 No Data                   4                       6                    No Data                 No Data
  TFBS[b](#nt103){ref-type="table-fn"}                                               ---                      Y                       ---                      ---                      ---                     ---                     Y                      ---                     ---                     ---
  Splicing (ESE or ESS)                                                              ---                     ---                      ---                      ---                      ---                     ---                    ---                     ---                     ---                     ---
  miRNA (miRanda)                                                                    ---                     ---                      ---                      ---                      ---                     ---                    ---                     ---                     ---                     ---
  miRNA (Sanger)                                                                     ---                     ---                      ---                      ---                      ---                     ---                    ---                     ---                     ---                     ---
  nsSNP                                                                              ---                     ---                      ---                      ---                      ---                     ---                    ---                      Y                       Y                      ---
  MAF[c](#nt104){ref-type="table-fn"} for Chinese in database                       0.366                   0.453                    0.276                    0.471                    0.163                   0.244                  0.188                   0.207                   0.159                   0.058
  MAF in our controls (n = 686)                                                     0.387                   0.452                    0.249                    0.460                    0.188                   0.257                  0.193                   0.227                   0.153                   0.067
  *p* value for HWE[d](#nt105){ref-type="table-fn"} test in our controls            0.432                   0.317                    0.073                    0.544                    0.841                   0.484                  0.124                   0.328                   0.201                 **0.015**
  Genotyping method[e](#nt106){ref-type="table-fn"}                                  LDR                     LDR                      LDR                      LDR                      LDR                     LDR                    LDR                     LDR                     LDR                     LDR
  \% Genotyping value                                                              98.48%                   96.43%                   96.35%                   98.18%                  96.43%                  98.48%                  98.18%                 96.81%                  95.29%                  98.18%

http://[www.regulomedb.org/](http://www.regulomedb.org/);

TFBS: Transcription Factor Binding Site (<http://snpinfo.niehs.nih.gov/snpinfo/snpfunc.htm>);

MAF: minor allele frequency, *NAT2* rs4540438 A\>C MAF is in CHB+JPT population;

HWE: Hardy--Weinberg equilibrium;

LDR: ligation detection reaction; Bold values are statistically significant (*p*\<0.05).

Associations between NAT2 tagging polymorphisms and risk of ESCC {#s3b}
----------------------------------------------------------------

The genotype distributions of *NAT2* rs1565684 T\>C in the cases and the controls are shown in [Table 3](#pone-0087783-t003){ref-type="table"}. In the single locus analyses, there was a borderline statistically significant difference in genotype frequencies of *NAT2* rs1565684 T\>C SNP between the cases and the controls (*p* = 0.057). When the *NAT2* rs1565684 TT homozygote genotype was used as the reference group, the TC genotype was not associated with the risk for ESCC (TC vs. TT: OR = 1.14, 95% CI = 0.90--1.44, *p* = 0.269); the CC genotype was associated with a significantly increased risk for ESCC (CC vs. TT: OR = 1.95, 95% CI = 1.08--3.51, *p* = 0.026). In the dominant model, the *NAT2* rs1565684 TC/CC variants were not associated with the risk of ESCC, compared with the *NAT2* rs1565684 TT genotype (TC/CC vs. TT: OR = 1.20, 95% CI = 0.96--1.51, *p* = 0.107). In the recessive model, when the *NAT2* rs1565684 TT/TC genotypes were used as the reference group, the CC homozygote genotype was associated with an 86% increased risk of ESCC (CC vs. TT/TC: OR = 1.86, 95% CI = 1.04--3.33, *p* = 0.037) ([Table 3](#pone-0087783-t003){ref-type="table"}). After adjusted for age, sex, smoking and drinking status, the CC genotype was associated with a borderline significantly increased risk for ESCC (CC vs. TT: adjusted OR = 1.77, 95% CI = 0.97--3.21, *p* = 0.063 and CC vs. TT/TC: adjusted OR = 1.68, 95% CI = 0.93--3.04, *p* = 0.085). After the Bonferroni correction, in all comparison models, *NAT2* rs1565684 T\>C SNP was not associated with ESCC risk (*p*\>0.05).

10.1371/journal.pone.0087783.t003

###### Logistic regression analyses of associations between *NAT2* rs1041983 C\>T, rs11780884 A\>G, rs11996129 T\>C, rs12674710 C\>A, rs1390359 C\>A, rs1390360 G\>A, rs1565684 T\>C, rs1799930 G\>A, rs1799931 G\>A and rs4540438 A\>C polymorphisms and risk of ESCC.
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  Genotype                  Cases (n = 629)   Controls (n = 686)   Crude OR (95%CI)   *p*    Adjusted OR[a](#nt107){ref-type="table-fn"} (95%CI)      *p*                         
  ------------------------ ----------------- -------------------- ------------------ ------ ----------------------------------------------------- ----------- ------------------- -------
  *NAT2* rs1041983 C\>T                                                                                                                                                           
  CC                              209                33.8                259          38.3                          1.00                                             1.00         
  CT                              315                50.9                311          46.0                    1.26 (0.99--1.60)                      0.064     1.23 (0.96--1.57)   0.097
  TT                              95                 15.3                106          15.7                    1.11 (0.80--1.55)                      0.535     1.13 (0.81--1.59)   0.478
  CT+TT                           410                66.2                417          61.7                    1.22 (0.97--1.53)                      0.089     1.21 (0.96--1.52)   0.114
  CC+CT                           524                84.7                570          84.3                          1.00                                             1.00         
  TT                              95                 15.3                106          15.7                    0.98 (0.72--1.32)                      0.869     1.00 (0.74--1.37)   0.979
  *NAT2* rs11780884 A\>G                                                                                                                                                          
  AA                              165                27.3                206          31.0                          1.00                                             1.00         
  AG                              303                50.2                316          47.6                    1.20 (0.93--1.55)                      0.172     1.18 (0.91--1.53)   0.219
  GG                              136                22.5                142          21.4                    1.20 (0.88--1.63)                      0.261     1.22 (0.89--1.68)   0.215
  AG+GG                           439                72.7                458          69.0                    1.20 (0.94--1.53)                      0.148     1.19 (0.93--1.53)   0.163
  AA+AG                           468                77.5                522          78.6                          1.00                                             1.00         
  GG                              136                22.5                142          21.4                    1.07 (0.82--1.39)                      0.627     1.10 (0.84--1.45)   0.479
  *NAT2* rs11996129 T\>C                                                                                                                                                          
  TT                              345                56.2                377          57.7                          1.00                                             1.00         
  TC                              236                38.4                227          34.8                    1.14 (0.90--1.44)                      0.284     1.16 (0.92--1.47)   0.220
  CC                              33                 5.4                  49          7.5                     0.74 (0.46--1.17)                      0.196     0.80 (0.50--1.29)   0.366
  TC+CC                           269                43.8                276          42.3                    1.07 (0.85--1.33)                      0.579     1.10 (0.88--1.38)   0.411
  TT+TC                           581                94.6                604          92.5                          1.00                                             1.00         
  CC                              33                 5.4                  49          7.5                     0.70 (0.44--1.10)                      0.125     0.76 (0.47--1.21)   0.243
  *NAT2* rs12674710 C\>A                                                                                                                                                          
  CC                              166                27.2                202          29.7                          1.00                                             1.00         
  CA                              309                50.6                330          48.5                    1.14 (0.88--1.47)                      0.321     1.11 (0.86--1.45)   0.421
  AA                              136                22.3                148          21.8                    1.19 (0.82--1.53)                      0.482     1.15 (0.84--1.58)   0.388
  CA+AA                           445                72.8                478          70.3                    1.13 (0.89--1.44)                      0.314     1.13 (0.88--1.44)   0.351
  CC+CA                           475                77.7                532          78.2                          1.00                                             1.00         
  AA                              136                22.3                148          21.8                    1.03 (0.79--1.34)                      0.831     1.07 (0.82--1.41)   0.604
  *NAT2* rs1390359 C\>A                                                                                                                                                           
  CC                              412                67.4                434          66.1                          1.00                                             1.00         
  CA                              179                29.3                199          30.3                    0.95 (0.74--1.21)                      0.664     0.96 (0.75--1.23)   0.735
  AA                              20                 3.3                  24          3.7                     0.88 (0.48--1.61)                      0.676     1.03 (0.55--1.91)   0.930
  CA+AA                           199                32.6                223          33.9                    0.94 (0.74--1.19)                      0.605     0.97 (0.76--1.23)   0.771
  CC+CA                           591                96.7                633          96.3                          1.00                                             1.00         
  AA                              20                 3.3                  24          3.7                     0.89 (0.49--1.63)                      0.713     1.04 (0.56--1.93)   0.896
  *NAT2* rs1390360 G\>A                                                                                                                                                           
  GG                              343                55.4                377          55.8                          1.00                                             1.00         
  GA                              242                39.1                251          37.1                    1.06 (0.84--1.33)                      0.620     1.07 (0.85--1.36)   0.555
  AA                              34                 5.5                  48          7.1                     0.78 (0.49--1.24)                      0.289     0.88 (0.55--1.42)   0.609
  GA+AA                           276                44.6                299          44.2                    1.02 (0.82--1.26)                      0.897     1.05 (0.84--1.31)   0.703
  GG+GA                           585                94.5                628          92.9                          1.00                                             1.00         
  AA                              34                 5.5                  48          7.1                     0.76 (0.48--1.20)                      0.237     0.86 (0.54--1.37)   0.519
  *NAT2* rs1565684 T\>C                                                                                                                                                           
  TT                              366                59.9                437          64.3                          1.00                                             1.00         
  TC                              214                35.0                224          32.9                    1.14 (0.90--1.44)                      0.269     1.14 (0.90--1.45)   0.270
  CC                              31                 5.1                  19          2.8                   **1.95 (1.08--3.51)**                  **0.026**   1.77 (0.97--3.21)   0.063
  TC+CC                           245                40.1                243          35.7                    1.20 (0.96--1.51)                      0.107     1.19 (0.95--1.50)   0.130
  TT+TC                           580                94.9                661          97.2                          1.00                                             1.00         
  CC                              31                 5.1                  19          2.8                   **1.86 (1.04--3.33)**                  **0.037**   1.68 (0.93--3.04)   0.085
  *NAT2* rs1799930 G\>A                                                                                                                                                           
  GG                              375                62.5                407          60.5                          1.00                                             1.00         
  GA                              200                33.3                227          33.7                    0.96 (0.76--1.21)                      0.711     0.97 (0.76--1.23)   0.804
  AA                              25                 4.2                  39          5.8                     0.70 (0.41--1.17)                      0.173     0.78 (0.45--1.33)   0.353
  GA+AA                           225                37.5                266          39.5                    0.92 (0.73--1.15)                      0.459     0.94 (0.75--1.19)   0.620
  GG+GA                           575                95.8                634          94.2                          1.00                                             1.00         
  AA                              25                 4.2                  39          5.8                     0.71 (0.42--1.18)                      0.186     0.78 (0.46--1.33)   0.367
  *NAT2* rs1799931 G\>A                                                                                                                                                           
  GG                              406                67.3                462          71.1                          1.00                                             1.00         
  GA                              181                30.0                177          27.2                    1.16 (0.91--1.49)                      0.228     1.15 (0.89--1.47)   0.289
  AA                              16                 2.7                  11          1.7                     1.66 (0.76--3.61)                      0.205     1.35 (0.61--2.99)   0.465
  GA+AA                           197                32.7                188          28.9                    1.19 (0.94--1.52)                      0.151     1.16 (0.91--1.48)   0.240
  GG+GA                           587                97.3                639          98.3                          1.00                                             1.00         
  AA                              16                 2.7                  11          1.7                     1.58 (0.73--3.44)                      0.246     1.29 (0.59--2.86)   0.526
  *NAT2* rs4540438 A\>C                                                                                                                                                           
  AA                              522                85.4                596          87.6                          1.00                                             1.00         
  AC                              86                 14.1                 77          11.3                    1.28 (0.92--1.77)                      0.148     1.31 (0.93--1.83)   0.118
  CC                               3                 0.5                  7           1.0                     0.49 (0.13--1.90)                      0.302     0.52 (0.13--2.04)   0.344
  AC+CC                           89                 14.6                 84          12.4                    1.21 (0.88--1.67)                      0.243     1.24 (0.90--1.72)   0.195
  AA+AC                           608                99.5                673          99.0                          1.00                                             1.00         
  CC                               3                 0.5                  7           1.0                     0.48 (0.12--1.84)                      0.282     0.50 (0.13--1.97)   0.319

Adjusted for age, sex, smoking status and alcohol consumption; Bonferroni correction was performed to correct the *p* value (*p* ~correct~); For the 10 *NAT2* SNPs, *p* ~correct~\>0.05 in all comparison models; Bold values are statistically significant (*p*\<0.05).

For the other nine SNPs, in the single locus analyses, there was no statistically significant difference in genotype frequencies of these nine SNPs between the cases and the controls (*p*\>0.05). Logistic regression analyses revealed that none of these nine polymorphic sites was associated with the susceptibility to ESCC. In all comparison models, the nine SNPs were not associated with ESCC risk (*p*\>0.05) before and after the Bonferroni correction ([Table 3](#pone-0087783-t003){ref-type="table"}).

Stratification analyses of NAT2 rs1565684 T\>C polymorphisms and risk of ESCC {#s3c}
-----------------------------------------------------------------------------

To evaluate the effects of *NAT2* rs1565684 T\>C genotypes on ESCC risk according to different age, sex, smoking and alcohol drinking status; we performed the stratification analyses ([Table 4](#pone-0087783-t004){ref-type="table"}). A significantly increased risk of ESCC associated with the *NAT2* rs1565684 T\>C polymorphism was evident among older patients and patients who never drunk ([Table 4](#pone-0087783-t004){ref-type="table"}).

10.1371/journal.pone.0087783.t004

###### Stratified analyses between *NAT2* rs1565684 T\>C polymorphism and ESCC risk by sex, age, smoking status and alcohol consumption.

![](pone.0087783.t004){#pone-0087783-t004-4}

  Variable               *NAT2* rs1565684 T\>C (case/control)[a](#nt108){ref-type="table-fn"}   Adjusted OR[b](#nt109){ref-type="table-fn"} (95% CI); *p*; *p* ~h~ [c](#nt110){ref-type="table-fn"}                                                                                                                                                                                                  
  --------------------- ---------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------- ------- --------- ------ ---------------------------------------------- ----------------------------------------------------------- ----------------------------------------------------------- -----------------------------------------------------------
  Sex                                                                                                                                                                                                                                                                                                                                                                                                
  Male                                                 263/290                                                                                143/151                                                 26/14   169/165   1.00   1.04 (0.78--1.38); *p*: 0.815; *p* ~h~:0.265         1.86 (0.94--3.68); *p*: 0.077; *p* ~h~:0.621                1.11 (0.84--1.46); *p*: 0.472; *p* ~h~:0.402                1.83 (0.93--3.61); *p*: 0.080; *p* ~h~:0.519
  Female                                               103/147                                                                                 71/73                                                   5/5     76/78    1.00   1.41 (0.93--2.13); *p*: 0.106; *p* ~h~:0.265         1.53 (0.43--5.45); *p*: 0.516; *p* ~h~:0.621                1.42 (0.94--2.13); *p*: 0.094; *p* ~h~:0.402                1.34 (0.38--4.75); *p*: 0.648; *p* ~h~:0.519
  Age                                                                                                                                                                                                                                                                                                                                                                                                
  \<63                                                 187/231                                                                                97/124                                                  15/8    112/132   1.00   0.92 (0.66--1.30); *p*: 0.645; *p* ~h~:0.165         1.73 (0.70--4.31); *p*: 0.239; *p* ~h~:0.591                0.98 (0.70--1.36); *p*: 0.891; *p* ~h~:0.234                1.78 (0.72--4.39); *p*: 0.211; *p* ~h~:0.458
  ≥63                                                  179/206                                                                                117/100                                                 16/11   133/111   1.00   1.38 (0.99--1.94); *p*: 0.059; *p* ~h~:0.165         1.73 (0.78--3.87); *p*: 0.178; *p* ~h~:0.591          **1.42 (1.02--1.96);** ***p*** **: 0.035;** *p* ~h~:0.234         1.54 (0.70--3.41); *p*: 0.284; *p* ~h~:0.458
  Smoking status                                                                                                                                                                                                                                                                                                                                                                                     
  Never                                                205/323                                                                                125/160                                                 14/11   139/171   1.00   1.22 (0.91--1.64); *p*: 0.190; *p* ~h~:0.378         2.03 (0.90--4.59); *p*: 0.088; *p* ~h~:0.636                1.27 (0.95--1.70); *p*: 0.102; *p* ~h~:0.398                1.89 (0.84--4.25); *p*: 0.122; *p* ~h~:0.729
  Ever                                                 161/114                                                                                 89/64                                                  17/8    106/72    1.00   1.05 (0.70--1.58); *p*: 0.821; *p* ~h~:0.378         1.51 (0.62--3.69); *p*: 0.368; *p* ~h~:0.636                1.10 (0.74--1.63); *p*: 0.634; *p* ~h~:0.398                1.48 (0.61--3.58); *p*: 0.382; *p* ~h~:0.729
  Alcohol consumption                                                                                                                                                                                                                                                                                                                                                                                
  Never                                                252/341                                                                                142/169                                                 21/11   163/180   1.00   1.17 (0.88--1.56); *p*: 0.273; *p* ~h~:0.908   **2.38 (1.10--5.14);** ***p*** **: 0.028;** *p* ~h~:0.150         1.25 (0.95--1.65); *p*: 0.114; *p* ~h~:0.664          **2.25 (1.05--4.83);** ***p*** **: 0.038;** *p* ~h~:0.149
  Ever                                                  114/96                                                                                 72/55                                                  10/8     82/63    1.00   1.12 (0.71--1.77); *p*: 0.615; *p* ~h~:0.908         1.14 (0.43--3.02); *p*: 0.799; *p* ~h~:0.150                1.13 (0.73--1.74); *p*: 0.596; *p* ~h~:0.664                1.09 (0.42--2.85); *p*: 0.866; *p* ~h~:0.149

The genotyping was successful in 611 (97.1%) ESCC cases, and 680 (99.1%) controls for *NAT2* rs1565684 T\>C;

Adjusted for age, sex, smoking status and alcohol consumption (besides stratified factors accordingly) in a logistic regression model;

*p* ~h~ for heterogeneity.

Discussion {#s4}
==========

In this hospital-based case-control study of ESCC, we found that ten selected *NAT2* tagging SNPs were not associated with the risk of ESCC after the Bonferroni correction. *NAT2* rs1565684 CC genotype was associated with a borderline significantly increased risk for ESCC. A significantly increased risk of ESCC associated with the *NAT2* rs1565684 T\>C polymorphism was evident among older patients and patients who never drunk. To the best of our knowledge, it\'s the first positive finding of *NAT2* rs1565684 T\>C polymorphism and ESCC risk.

NAT2 is involved in the metabolism of a major class of tobacco smoke carcinogens (the aromatic amines) and *NAT2* variant alleles result in slow clearance of aromatic amines. In humans, the *NAT2* gene encodes a phase II enzyme that plays an essential role in aromatic, heterocyclic amines and hydrazines metabolism [@pone.0087783-Liu1]. NAT2 influences the detoxification of aromatic and heterocyclic amine carcinogens (which are present in tobacco smoke) by two pathways: the metabolism reaction may result in the detoxification by N-acetylation, or bioactivation by O-acetylation often preceded by CYP450 hydroxylation [@pone.0087783-Liu1].

Previous case-control reports have yielded inconsistent results regarding the association of *NAT2* SNPs with cancers, possibly because of the small number of subjects, which would compromise the power of the statistical analyses in these studies. In the esophagus, the slow *NAT2* acetylator genotype was more susceptible to esophageal cancer in Japan [@pone.0087783-Morita1]. However, in another study in Taiwan, *NAT2* polymorphisms did not affect the risk of esophageal cancer, irrespective of environmental factors [@pone.0087783-Lee1]. In a more recent study in India, *NAT2* acetylator genotypes did not influence susceptibility to esophageal cancer. *NAT2* polymorphisms did not significantly modulate the cancer risk after interaction with environmental factors, such as tobacco, alcohol or occupational exposure [@pone.0087783-Jain1]. In another study in the Kashmir Valley, none of the three *NAT2* polymorphic alleles (rs1799929, rs1799930 and rs1799931) was found to be independently associated with risk of esophageal and gastric cancers [@pone.0087783-Malik1], which was also in accordance with our results. Meta analysis also suggested that *NAT2* genotypes are not associated with lung cancer [@pone.0087783-Cui1], gastric cancer [@pone.0087783-Zhong1], breast cancer [@pone.0087783-Zhang1], prostate cancer [@pone.0087783-Gong1] and oral cancer [@pone.0087783-Liao1]. *NAT2* rs1565684 T\>C is in linkage disequilibrium with another important SNP *NAT2* rs4345600 A\>G (NS 12, −9306 A\>G) (r^2^ = 0.845) in Chinese Han Beijing population. Although *NAT2* rs1565684 T\>C SNP is functional using SNP function prediction websites (<http://snpinfo.niehs.nih.gov/snpinfo/snpfunc.htm> and <http://www.regulomedb.org/>). The etiology of *NAT2* rs1565684 T\>C SNP is still not well known and need further investigation.

This case-control study had several limitations. First, the patients and controls were enrolled from hospitals; inherent bias may have resulted in spurious findings. Second, the statistical power of our study was limited because of the moderate sample size and absence of a validation cohort; further replication studies are needed. Third, the viral infections and immune parameters information were not available, which restricted the power of our analyses. Finally, we did not obtain detailed information on cancer metastasis and survival, which restricted further analyses of the roles of the *NAT2* polymorphisms in ESCC progression and prognosis.

In conclusion, our study provides evidence that *NAT2* tagging SNPs may not contribute to the risk of ESCC. Larger well-designed studies are required to confirm the current findings.
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